- Conditions
- Blood Loss, Surgical
- Interventions
- Ecallantide, Placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide, Phosphate Buffer Saline (PBS),
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Wheaton, Maryland
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more
- Conditions
- ACE Inhibitor Induced Angioedema
- Interventions
- ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg, placebo, placebo match for 30 mg ecallantide arm, placebo match for 10 mg ecallantide arm
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 39
- States / cities
- Montgomery, Alabama • Colton, California • Los Angeles, California + 33 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 42
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more
- Conditions
- Bloodloss, Surgical Procedures, Operative
- Interventions
- Ecallantide, Cyklokapron(R)
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Bloodloss, Surgical Procedures, Operative
- Interventions
- ecallantide, placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 40
- States / cities
- Little Rock, Arkansas • Bell Gardens, California • Granada Hills, California + 35 more
- Conditions
- Angioedema
- Interventions
- ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
- Drug
- Lead sponsor
- Bernstein, Jonathan A., M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio
- Conditions
- Hereditary Angioedema Types I and II
- Interventions
- Ecallantide subcutaneous dosing
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Mineola, New York